Stevanato Group (NYSE:STVN) Price Target Cut to $23.50 by Analysts at UBS Group

Stevanato Group (NYSE:STVN) had its target price trimmed by UBS Group from $24.00 to $23.50 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other brokerages have also recently commented on STVN. Wolfe Research began coverage on Stevanato Group in a research note on Friday, December 13th. They issued an “outperform” rating and a $28.00 price target for the company. Bank of America increased their price target on Stevanato Group from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $23.00 target price (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of €27.75 ($30.16).

Stevanato Group Stock Up 4.9 %

Shares of STVN opened at €21.72 ($23.61) on Friday. Stevanato Group has a 52 week low of €16.56 ($18.00) and a 52 week high of €33.49 ($36.40). The stock has a market capitalization of $6.58 billion, a price-to-earnings ratio of 46.21, a PEG ratio of 7.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The stock has a fifty day moving average of €21.38 and a 200-day moving average of €20.52.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The company had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. As a group, sell-side analysts anticipate that Stevanato Group will post 0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of STVN. Zions Bancorporation N.A. bought a new position in shares of Stevanato Group in the 3rd quarter worth about $1,049,000. Sivik Global Healthcare LLC bought a new position in shares of Stevanato Group in the 3rd quarter worth about $2,800,000. King Wealth Management Group raised its position in shares of Stevanato Group by 30.2% in the 3rd quarter. King Wealth Management Group now owns 94,800 shares of the company’s stock worth $1,896,000 after acquiring an additional 22,000 shares in the last quarter. Royce & Associates LP raised its position in shares of Stevanato Group by 45.8% in the 3rd quarter. Royce & Associates LP now owns 343,159 shares of the company’s stock worth $6,863,000 after acquiring an additional 107,869 shares in the last quarter. Finally, Natixis Advisors LLC raised its position in shares of Stevanato Group by 20.3% in the 3rd quarter. Natixis Advisors LLC now owns 51,343 shares of the company’s stock worth $1,027,000 after acquiring an additional 8,669 shares in the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.